PYXS Earnings Date: Nov 2, 2026 (Estimated) — Pyxis Oncology, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is PYXS's next earnings date?
Pyxis Oncology, Inc. (PYXS) is expected to report Q3 2026 earnings on Monday, November 2, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.27.
How did PYXS do in its last earnings report?
In its most recent report on Aug 13, 2026 (Q2 2026), Pyxis Oncology, Inc. posted EPS of -$0.40 versus the -$0.35 estimate, a miss of 14.3%. Revenue was $0 against a $33,333 estimate. The stock's 1-day post-earnings move was -5.3%.
How much does PYXS stock move after earnings?
PYXS beat EPS estimates in 2 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 5.8% (up or down) in the day after earnings.
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | Q2 2026 | -0.35 | -0.40 | -14.29% | $0 | ❌ Miss | -5.35% | +5.97% | +0.94% |
| 2026-05-14 | Q1 2026 | -0.35 | -0.37 | -5.71% | $0 | ❌ Miss | -15.65% | -23.66% | -32.82% |
| 2026-03-23 | Q4 2025 | -0.34 | -0.29 | +14.71% | $11.0M | ✅ Beat | -3.40% | -10.88% | +16.33% |
| 2025-11-03 | Q3 2025 | -0.35 | -0.35 | +0.00% | $0 | ➖ Inline | +7.02% | +9.83% | +9.83% |
| 2025-03-18 | Q4 2024 | -0.29 | -0.59 | -103.45% | $0 | ❌ Miss | -8.62% | +3.45% | -21.12% |
| 2024-11-12 | Q3 2024 | -0.30 | -0.35 | -16.67% | $0 | ❌ Miss | -2.53% | -13.71% | -65.82% |
| 2024-08-14 | Q2 2024 | -0.28 | -0.29 | -3.57% | $0 | ❌ Miss | +2.08% | +8.04% | +12.50% |
| 2024-05-14 | Q1 2024 | -0.22 | -0.06 | +72.73% | $16.1M | ✅ Beat | -2.10% | -2.33% | -10.26% |
Showing last 8 quarters.